Various cationic lipophilic compounds can reverse the multidrug resistance of cancer cells. Possible interaction between these compounds, which are known as modulators, has been assessed by measuring leakage of Sulphan blue from anionic liposomes, induced both by verapamil alone and by verapamil in combination with diltiazem, quinine, thior idazine or clomipramine. An equation was derived to quantify the permeation doses and Hill coefficients of the drugs and mixtures between them by simultaneous fitting of the experimental data. The interaction was tested by two methods, the competition plot and the isobole method; both showed synergy between verapamil and each of diltiazem, qui nine and thioridazine. The dose factor of potentiation for verapamil determined within membranes was 4.0 ± 0.4 with diltiazem, 3.2 ± 0.4 with quinine and 2.4 ± 0.3 with thior idazine. The results suggest that the effectiveness of reversing multidrug resistance may be increased with modulators such as verapamil and diltiazem that have a much greater ef fect in combination than what would be expected from their effects when considered sep arately. 
Introduction
A major problem in the treatment of cancer is that of multidrug resistance, which remains imperfectly understood, though in some instances it certainly involves altered membrane transport in tumour cells (Pajeva et al 2004; Ferreira et al 2005) . Toxicity-lowering export of drugs is mediated by the membrane protein P-glycoprotein (Higgins and Gottesmann 1992; Qu et al 2003) , a member of the class of ABC transporters. Export of drugs by this protein is believed to result from interaction with the protein after partitioning into the membrane (Lugo and Sharom 2005) . Study of this process in cancer cell lines (Ferreira et al 2005) has been useful, but it is made more difficult by the complicated structures of membranes in vivo, so for exploring interactions between drugs at the lipid bilayer it can be more informative to use of model membranes of known structure (Pajeva et al 2004) , and we have used anionic liposomes (Castaing et al 2003) for this purpose. The major loss in complexity when compared with real cell membranes comes from the absence of proteins, but this should not greatly affect the interpretation, because lipophilic amphiphiles such modulators primarily interact with the lipids, and not with the proteins. We shall discuss more detail later how far one can extrapolate from model membranes to real cells (see Discussion).
In biomedical research, including investigation of cancer, studies of the combined action of biologically active agents, such as drugs, environmental pollutants or radiation have become increasingly important (Sühnel 1998), as Synergy between verapamil and other multidrug -resistance modulators in model membranes MADELEINE CASTAING 1,2,* , ALAIN LOISEAU 3 and ATHEL CORNISH -BOWDEN combinations of agents are being increasingly used clinically for the therapeutic advantages they may provide over single agents (Berenbaum 1989) . The usual approach for assessing a possible interaction in combination experiments is to calculate, from the effects of single agents, what is expected for the combination effect in the case of no interaction. An observed effect larger than expected is taken as evidence of synergism, and a smaller effect as evidence of antagonism. Five principal approaches have been used to predict the expected effect: comparison of the combined action with the most effective single constituent; multiplication of effects; summation of effects; the median-effect principle; and the isobole method (Berenbaum 1989; Sühnel 1990) . Among these, the only generally applicable procedure is the isobole method, as it requires no assumptions about the shapes of the dose-response curves (Berenbaum 1989; Loewe 1928) . It only requires experimental data for the agents used alone and in different dose combinations at equally effective levels, but for assessing synergy or antagonism both the expected effects and the actual effects need to be determined with high precision. Modulators such as verapamil, quinine and others, which reverse the multidrug resistance of cancer cells (Sharom 1997) , bind to membranes in the region between the head groups of the phospholipids at the membrane surface and the acyl chains of the phospholipids in the core of the membrane. The spatial positioning of these molecules in the binding site may vary according to their sizes and shapes, and according to their hydrophobicity and electric charge (Castaing et al 2003 (Castaing et al , 2005 . We therefore set out to assess the possibility of synergy between multidrug resistance modulators in terms of drug-membrane interactions, by testing the ability of verapamil to induce dye leakage from anionic liposomes, alone (Klohs et al 1986) and in combination with other modulators, diltiazem (Klohs et al 1986) , quinine (Bennis et al 1997) , thioridazine (Ramu et al 1984) and clomipramine (Tsuruo 1983) . We derived an equation that allows all the data to be explained simultaneously in terms of cooperative binding of the separate drugs as well as synergistic interactions between them. We show that in addition to the isobole method, widely used in pharmacological studies, the competition plot (Chevillard et al 1993; Cárdenas 2001) may be a useful method for assessing synergy or antagonism between the effects of drugs.
Materials and methods

Materials
L-α-Phosphatidylcholine prepared from fresh egg yolk, L-α-phosphatidic acid prepared from egg yolk lecithin, verapamil, diltiazem, quinine and clomipramine were purchased as their hydrochlorides from Sigma (St Louis, MO, USA). Thioridazine hydrochloride and the dye anhydro-4-4´-bis(diethyl-amino)triphenyl-methanol-2´´, 4´´-disulphonic acid monosodium salt (Sulphan blue) were purchased from Aldrich (Steinheim, Germany). Cholesterol was obtained from Fluka (Buchs, Switzerland). Diethyl ether, Na 2 HPO 4 .2H 2 O and NaH 2 PO 4 .H 2 O were purchased from Merck (Darmstadt, Germany), Sephadex PD-10 columns (G-25M) from Pharmacia (Uppsala, Sweden) and polycarbonate porous membranes from Nuclepore Corporation (Pleasanton, CA).
Each of the modulators was dissolved in water.
Liposomes loaded with Sulphan blue
Large unilamellar vesicles composed of phosphatidylcholine, phosphatidic acid and cholesterol (8:1:1) were prepared by reverse-phase evaporation, as previously described (Castaing et al 2000) . The external dye was removed by passage through two Sephadex G-25 columns eluted with 100 mM phosphate buffer (pH 7.4 at 37°C).
Permeability measurements
The absorbance of Sulphan blue at 640 nm was determined by recording the visible absorption spectra of the samples with a Uvikon 933 spectrophotometer (Milan, Italy). Permeability was measured in 1 ml suspensions of large unilamellar vesicles. The two drugs, alone or in combination, or the solvent, were mixed with 0.5 ml buffer. Following the addition of 0.5 ml liposomes, the sample was stirred for 3 min at 37°C using a Salvis SBK shaker bath (Reussbühl-Luzern, Switzerland). The external dye was removed as previously described (Castaing et al 2000) . In these experiments, leakage was induced by 0-11 mM drug (or 0-1.7 mol drug/ mol lipid), alone or in combination. It was quantified after a 3 min incubation (initial rate of leakage) at 37°C (pH 7.4).
Analysis of dose-response curves
The initial rate of leakage of Sulphan blue induced by verapamil was quantified, alone and at five or six constant concentrations of diltiazem, quinine, thioridazine or clomipramine, following an experimental approach similar to that of Pöch et al (1990) . The variations in the initial rate of Sulphan blue leakage with different drug concentrations were fitted by non-linear least squares regression. in which a, a 0.5 and h A are the symbols for verapamil with the same meanings as in eqn (1); b, b 0.5 and h B are the corresponding symbols for the second drug, the terms in b resulting from an obvious generalization of the equation to allow for the presence of the second drug; and K AB and h A,B are a binding constant and a Hill coefficient that characterize interaction between the two drugs, the terms in ab allowing for the possibility that both drugs can bind simultaneously.
Theory
Analysis of dose-response curves
Isobole analysis
In the isobole method, the effects of drug combinations are expressed graphically in a two-dimensional plot called an 'isobologram', in which isoboles are the curves connecting equally effective dose combinations of the two drugs (Loewe 1928) , isobolograms being typically drawn at a fixed effect level of 50%. The drug doses on the two axes can be expressed as the specific concentrations of the agents so that equally effective doses of the drugs, applied singly, are equal to unity (Elion et al 1954) ; in other words, the specific concentration of a modulator is its concentration in the mixture divided by the concentration that would be needed for it to produce the same effect by itself. Points below the straight line of zero interaction correspond to synergistic interaction and points above it to antagonism.
Results
Drug permeation properties of mixtures of verapamil with a second multidrug-resistance modulator
Results for verapamil with diltiazem are illustrated in fi gure 1, and qualitatively similar behaviour was observed for verapamil in combination with the other drugs. It is evident from the sigmoid nature of the curves for verapamil and diltiazem in fi gure 1 that these drugs bind with a high degree of cooperativity, and this was true for each of the five drugs considered by itself. When the data for each experiment were fitted simultaneously to eqn (2) it was found in each case to describe the results with good accuracy (R 2 = 0.950-0.991; P < 0.001; n = 21-29); the permeation parameters are given in table 1.
If the two drugs were to bind exclusively at the same site, then the terms in ab would be negligible, but this is excluded by the fact that all the K AB values in the table are finite, i.e. each 1/K AB is significantly different from zero. One might naively expect that K AB , which has the dimensions of a squared concentration, might simply be the product a 0.5 b 0.5 , but it is much smaller than this product for all of the four drug combinations tabulated, a clear indication of synergy between the effects of the different drugs. The Hill coefficients for verapamil and diltiazem are very large, beyond the range normally observed for binding to a macromolecule, and there is signifi cant cooperativity for the other drugs also. For the verapamil-diltiazem combination it is tempting to attach signifi cance to the fact that the Hill coeffi cients for the separate drugs are both about 6 and that for the combination about half that, and in fact the data fi t fairly well to an equation in which the Hill coeffi cients are constrained to exactly these values. However, there is no corresponding suggestion from the other drug combinations.
The synergy of binding between verapamil and diltiazem is obvious in fi gure 1. Consider, for example, the results at 2.08 mM diltiazem. In the absence of verapamil this concentration of diltiazem produces only 7% dye leakage, the same as given by 0.95 mM verapamil in the absence of diltiazem. A concentration of verapamil of 1.90 mM, i.e. double 0.95 mM, a 'sham combination' in the terminology of Berenbaum (1989) , gives 68% leakage, but a combination of 0.95 mM verapamil with 2.08 mM diltiazem gives 80%: as this is greater than 67% it indicates synergy between the two drugs. 
Competition plot for multidrug-resistance modulators
The spatial positioning of multidrug-resistance modulators in the membrane binding site may vary depending on their structural and physicochemical characteristics (Castaing et al 2003; . As a result, two drugs may compete exclusively for the same part of the binding site. However, the synergy evident in fi gure 1 indicates that this is not the case for the drugs discussed here, and the data were accordingly analysed on the basis of eqn (2) If a 0 and b 0 are the reference concentrations of two drugs A and B with the same leakage rate when applied singly, then any combination of these drugs has the same leakage rate if they compete for the same site and their respective concentrations a and b are varied together in such a way that Figure 1 . Dose -response curves for verapamil and diltiazem. For the curve labelled 'diltiazem alone' the abscissa scale gives the concen tration of diltiazem; for all of the others the abscissa scale refers to verapamil and the curves are labelled with the diltiazem concentrations (in mM). In all cases leakage of Sulphan blue was measured and the initial rate of leakage was quantified after 3 min incubation at pH 7.4 (37°C). The curves were cal culated according to eqn (2) after simultaneous fitting of the experimental data obtained on one preparation of vesicles. Each point is the result of one measurement. The broken lines illustrate an analysis of the type proposed by Pöch and Holzmann (1980) The leakage of Sulphan blue through large unilamellar vesicle membranes was induced by 0-2.7 mM verapamil (drug A), alone or in combination with 0-9 mM diltiazem, quinine, thioridazine or clomipramine, i.e. the second multidrug -resistance modulator, drug B. The initial rate of leakage was quantified following incubation for 3 min at 37°C (pH 7.4). The permeation parameters of A, B and mixtures between them were determined according to eqn (2) by simultaneous fitting of the experimental data obtained on one vesicle preparation. Data are given ± SEM (n = 4), each error estimate being based on four separate determinations of the parameters from experiments with four different vesicle preparations. The surprisingly low value of h A in the bottom line can probably be explained by aggregation of clomipramine in the aqueous phase (Atherton and Barry 1985) , which reduced its thermodynamic activity.
where p varies from 0 to 1 and defi nes the concentrations of the two drugs in each mixture, i.e. p = (b/b 0 ) h B and et al 1993) . Application of eqn (2) with the parameter values of table 1 allowed a 0 , b 0 , a and b to be calculated as functions of p, this being done for leakage rates of 20% for the pure drugs. The leakage rates for the mixtures should not vary with p if the drugs compete exclusively for the same site. However, as illustrated in fi gure 2, the leakage rates of combinations of verapamil with other drugs varied greatly with p, being 4.4 ± 0.1 times higher with diltiazem at p = 0.5, 3.6 ± 0.1 times higher with quinine, 2.9 ± 0.1 times higher with thioridazine, and 2.2 ± 0.2 times higher with clomipramine. These very large deviations from the behaviour expected for simple competition, well outside experimental error, indicate that although multidrugresistance modulators bind to the same region of the membrane the binding is not exclusive (especially for the verapamil-diltiazem combination), and this allows synergy between these drugs. , and because of the experimental design (Figure 1) , the B values corresponding to any given A level had to be calculated from eqn (2) with the data of table 1. The variations of B with A were fitted to the following equation (R 2 = 0.993-1.000; P < 0.001; n =11):
Isoboles for multidrug-resistance modulators
where B = (b/b 0.5 ) h B and A = (a/a 0.5 ) h A , so that equally effective doses of A and B, applied singly, are equal to unity, and α is a parameter related to the interaction between them.
The dashed line connecting A = 1 to B = 1 represents all dose combinations with zero interaction, i.e. for the simpler equation B = 1 -A. This line is also called the dose-additivity line of Loewe (1928) . The curves for the mixtures of drugs all pass well below the zero-interaction straight line, i.e. the sum of the two normalized drug concentrations in each mixture is less than 1.0, even for the mixtures with the highest level of experimental error, those with clomipramine and verapamil, as indicated by the shaded region in the fi gure. Shading is not used in the other cases, as it would be barely visible at the scale of the fi gure for mixtures of thioridazine and verapamil, and not visible at all for the other two. The results therefore clearly indicate synergistic interactions between verapamil and each of the other four modulators. , where p specifies the proportion of the second drug in the mixture. If the modulators competed exclusively for the same binding site of the membrane, the amount of leakage would not vary with p (Chevillard et al 1993) . The curves drawn in this figure were calcu lated from eqns (2-4), and the shaded region around each curve shows the calculated standard errors of the mean. 
Dose ratio and dose factor of potentiation
Pöch's method (Pöch 1980) for quantifying the dose factor of potentiation of synergistic drugs from isobolograms was first applied to drugs showing non-cooperative binding, i.e. h A = h B = 1. The dose ratios were defined as DR A = 0.5/A* and DR B = 0.5/B*, the equal dose (A = B) inducing a given effect level being A = 0.5 and B = 0.5 for zero interacting drugs, and A = A* and B = B* for synergistic drugs, the doses A* and B* being determined graphically by the method illustrated for clomipramine in fi gure 3, and the dose factor DF value calculated as DF = DR A × DR B . In the present study, the cooperative dose-response curves precluded this simple approach, and to allow for cooperativity the dose ratios were expressed as DR A = (0.5/A*) 1/h A and DR B = (0.5/B*) 1/h B , and the A* and B* values were quantifi ed mathematically. As shown in fi gure 3, the coordinates of the intersection point of the identity line (A = B) with the isoboles of the modulators correspond to A* + B* mixtures (specifi ed by a star for the mixture of verapamil with clomipramine), and to a 0.5 + 0.5 mixture in the case of zero interaction. The value of A* was taken as the positive solution of the quadratic equation αA 2 + 2A -1 = 0 that results from substituting the identity-line condition B = A into eqn (5), and then B* could be calculated from eqn (5). The calculated values of DR A and DR B led to the dose factors shown in table 2: with the exception of clomipramine, the dose factors differ signifi cantly from unity, clearly indicating synergistic interactions of verapamil with three of the other drugs within membranes, the highest synergy being with diltiazem.
Discussion
The object of this study was to assess interaction between multidrug-resistance modulators (Klohs et al 1986; Bennis et al 1997; Ramu et al 1984; Tsuruo 1983 ) within the membrane of anionic liposomes. Apart from the importance of these molecules in cancer therapy, they have an additional theoretical interest by reason of the high cooperativity of their dose-response curves. Their action in combination was assessed by establishing the dose-response curves of verapamil alone and in combination with several concentrations of a second modulator, diltiazem, quinine, thioridazine or clomipramine (Pöch et al 1990) . The equation used to relate the variations in the dye leakage rate with different concentrations of verapamil and other drugs, eqn (2), described the experimental results well over the entire range of effect levels (fi gure 1). The permeation parameters (a 0.5 and h) of the drugs and mixtures between them were thus quantifi ed accurately (table 1) . The isobole method, used here to quantify the interaction between multidrug-resistance modulators (Loewe 1928) , normally requires experimental data for various dose combinations at equally effective levels and, according to Sühnel (1990) , obtaining these may be a laborious task. Here, however, interaction between modulators was investigated within the membrane of liposomes, a physicochemical system of limited complexity, and the dose combinations could be calculated simply at any given effect level with eqn (2) and the data of table 1. The isobologram was drawn at an effect level of 50%, with axes normalized to A = (a/a 0.5 ) h A and B = (b/b 0.5 ) h B so that equally effective doses of the drugs alone were equal to unity (Elion et al 1954) . This normalization and the high values of h A and h B (2.05 ≤ h ≤ 6.49) explains the very high curvature of the isoboles seen in fi gure 3. This figure may be perceived as misleading with respect to both the strength of the synergy and the rank order of the synergistic mixtures (table 2) , but this is inherent in the properties of the compounds studied, and a line for non-interacting drugs can only be obtained if this normalization is made. The variations of B with A are well explained by eqn (5), an equation derived here to describe the isoboles of the modulators. Note that if α = 1 then eqn (5) describes the isobole for synergistic mutually non-exclusive drugs, according to the concept of combination index applied to these agents by Chou and Talalay (1984) . In fi gure 3, the high error of the B values with the mixture between verapamil and clomipramine is likely to be due to the unusual shape of clomipramine, a tricyclic and nearly planar aromatic ring with an aliphatic side chain, as this structure favours its aggregation in the aqueous phase at low concentrations (Atherton and Barry 1985) . As the competition plots and isobolograms were based on the same experimental data, they did not differ in the experimental effort that they required. However, the greater computational effort needed to calculate the isobolograms reflects what would have been a difference in experimental effort if they had been from different experiments. In simple terms, the competition plot demands measurement of the actual behaviour in conditions that the simplest model predicts should produce no variation, whereas the isobole approach reverses this, as it requires experimental determination of the conditions that do in fact produce no variation. This difference exactly parallels the kinetic case: the competition plot (Chevillard et al 1993) looks for experimental deviations from a null expectation, whereas the constant-velocity plot (Whitehead 1984 ) looks for experimental conditions that give a null result.
The dose ratios indicate substantial potentiation of verapamil by the second modulator, the order of effectiveness being diltiazem > quinine > thioridazine > clomipramine. The rigid tricyclic rings in the chemical structures of thioridazine and clomipramine probably interfered with their insertion into the core of the membrane, decreasing their ability to interact with verapamil. The dose ratios of the second drugs, apart from clomipramine, were similar and significantly different from unity: this suggests that the ability to potentiate the effect of verapamil does not vary with the identity of the second drug unless it can aggregate in the aqueous phase (Atherton and Barry 1985) .
The dose factors of potentiation within liposomal membranes prove that there is synergy between verapamil and diltiazem, quinine and thioridazine (table 2), the order of effectiveness being diltiazem > quinine > thioridazine. The effectiveness of the modulators studied, with dose factors in the range of 2.4-4.0, is similar to that of anti-tumour drugs combinations applied to various cancer cell lines, with dose factors in the range of 2.1-10.5 (Müller et al 1976; De Vincenzo et al 1996; Photiou et al 1997) . Verapamil has already been found to increase the effects of papaverine (dose factor of 2.3) and isoprenaline (7.5) on smooth muscle (Pöch and Holzmann 1980) . In addition, combinations of antimalarial drugs such as quinine are highly synergistic, with dose factors in the range of 15-36 (Rollo 1955) . However, such high potentiation levels, leading to dose factors as high as 15-600, usually result from sequential blockade of steps along the same biochemical pathway (Pöch and Holzmann 1980; Rollo 1955) .
It follows that there is synergy between verapamil and other multidrug-resistance modulators within model membranes. If this synergy also occurs in the membranes of cancer cells -and in view of the physical chemistry involved, and the fact that the proteins present in cell membranes but not in our models are unlikely to interact strongly with multidrug-resistance molecules, which are highly lipophilic, there is little reason to expect otherwisethen a promising approach to combat multidrug resistance will be the clinical use of combinations of modulators such as verapamil and diltiazem that exhibit a greater effect together than that expected from study of the single agents. , and the dose factor of potentiation, calculated as DR A × DR B , were determined from the isoboles of the modulator mixtures at an effect level of 50% (fi gure 3). Data are given ± SEM (n = 4).
We now examine the extent to which results with model membranes shed light on the problem of drug effl ux from cancer cells. The ideal would, of course, be to carry out exact measurements on resistant cancer cells under reproducible conditions, but biological systems are too complex for such an approach to yield all the answers. Model membranes provide reproducibility and greater precision at the cost of moving further from pathological conditions. Their use cannot prove what happens in cancer treament, but it can suggest hypotheses that ought to be testable in clinical studies. To justify this point of view it may be helpful to describe briefl y the principle of the dye-leakage method: an impermeable dye is trapped inside the liposomes, and dye effl ux follows the partitioning of a multidrug-resistance modulator into the lipids if the strength of the modulatormembrane interaction is suffi cient. The dye effl ux does not, in any case, mimic the effl ux of the modulator tested or of an anticancer agent. Our aim was to show that there may be synergy between verapamil and other modulators within model membranes, and the synergy that we have shown to exist in this simple system suggests that it may also exist in the lipid phase of multidrug-resistant cells.
The basic assumption of a relationship between partitioning of drugs in model membranes and similar effects in vivo is well accepted. Most modulators are highly lipophilic, and Seydel et al (1994) have speculated that interactions between these compounds and the membrane phospholipids might contribute to the mechanism underlying multidrugresistance modulation. Pajeva et al (1996) suggest that drugmembrane interactions may lead to the reversal of multidrug resistance, either directly by changing the membrane fl uidity and permeability, or indirectly by modifying the structural organization of the lipids surrounding embedded proteins, thus changing their functional modes. Moreover, Drori et al (1995) have found a correlation between the ability of modulators (including verapamil and quinine) to induce dye leakage through the membrane of liposomes and their capacity to potentiate trimetrexate cytotoxicity in multidrugresistant T19 cells, suggesting that cytotoxicity potentiation by various modulators may involve an increase in membrane permeability to a variety of anticancer cytotoxic agents. Like various mild detergents, modulators induced a dosedependent dye leakage of carboxyfl uorescein encapsulated in liposomes. In addition, like specialized membrane fl uidizers, various modulators induced a dose-dependent membrane fl uidization, regardless of the lipid-bilayer source used (artifi cial liposomes, canalicular membrane vesicles or various wild-type and multidrug-resistant animal and human cells). The increased permeability induced by modulators favoured the passive entry of anticancer agents into sensitive or resistant cancer cells, the active effl ux of these compounds (modulators and anticancer agents) being mediated by the membrane protein P-glycoprotein.
Although the model membranes used here differ from cancer cells in their lipid composition, they offer a reasonable model in terms of physical chemistry. Biological membranes are essentially composed of phospholipids, cholesterol and embedded proteins, and can be considered as hydrophobic barriers separating two aqueous phases. The presence of proteins does not greatly affect the interpretation, because lipophilic amphiphiles such as modulators primarily interact with the lipid phase (head groups of the phospholipids and their acyl chains, cholesterol, and so on). Pajeva et al (1996) have likewise stressed that the ability of modulators to reverse resistance in tumour cells is likely to be mediated through their ability to interact with the membrane phospholipids. They concluded from their results that modulators within artifi cial membranes composed of neutral and negatively charged phospholipids provided a convenient model for screening compounds for their potential ability to reverse multidrug-resistance in tumour cells.
The relatively high drug:lipid molar ratios used in the study suggest weak interactions between the drug and lipid, and indeed, Pajeva et al (1996) stressed the moderate nature of the membrane interaction with verapamil; they showed that membrane interactions with verapamil occurred at drug:lipid molar ratios varying from 0.05:1 to 0.40:1. In the present study, this ratio amounted to 0.21-0.25:1 at the a 50 of verapamil, a result in agreement with the data of these authors. At the a 50 of the modulators, the drug:lipid ratio ranged here from 0.21:1 to 0.78:1. The highest value of 1.7:1 used in our experiments was not typical, being used only for clomipramine when inducing 90% dye leakage in 3 min, which was made necessary by the aggregation of clomipramine in the aqueous phase. It may also be noted that some drug:lipid ratios used here had high values because of the requirement for all the rates measured to correspond to initial rates, regardless of the modulator and of the leakage level (0-90%).
Drug-membrane interactions are controlled by numerous physico-chemical parameters related to the properties (i) of the modulator (partition coeffi cient or distribution coeffi cient, electric charge, size and shape, etc.), (ii) of the membrane (lipid composition, chain length and degree of saturation of the phospholipids, presence of cholesterol, which modifi es the dipolar potential of the membrane, membrane surface potential, etc.), and (iii) of the aqueous phases surrounding the membrane (ionic strength, pH, temperature, etc.). We believe that measurements of the initial rates of dye effl ux from liposomes offer the simplest way of quantifying the combined effects of all of these parameters. As we have shown, this method is quite capable of demonstrating the existence of synergistic interactions between modulators.
Experiments with lipid vesicles do not of course prove beyond any doubt that similar behaviour occurs in cancer cells, but they provide a useful indication. Given that all biological membranes (including cancer cells and multidrug resistant cancer cells) contain phospholipids, it seems justifi able to hypothesize that synergy between verapamil and other modulators may also occur in resistant tumour cells.
